Novo Nordisk's Wegovy Pill Boosts GLP-1 Market, Challenges Eli Lilly's Position
Novo Nordisk's Wegovy pill has driven significant growth in the GLP-1 drug market, prompting investors to reassess Eli Lilly's position following the launch of its own GLP-1 drug, Foundayo. Wegovy's rapid adoption has led to increased patient numbers and business growth for telehealth providers, while Foundayo's rollout has been more modest so far.
Tickers: $FOLD $LFMDP $LLY $NVO
Topics: Foundayo GLP-1 drugs market growth obesity treatment Wegovy